Page 12 - Read Online
P. 12
Pelizzaro et al. Hepatoma Res 2021;7:36 https://dx.doi.org/10.20517/2394-5079.2021.24 Page 7 of 7
35. El-Khoueiry A, Meyer T, Cheng A, et al. Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver
function in the phase 3 CELESTIAL study of cabozantinib vs placebo. Abstr ESMO 2020;31:S220. DOI
36. Kudo M, Matilla A, Santoro A, et al. Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma
(aHCC) and Child-Pugh B (CPB) status. J Clin Oncol 2019;37:327. DOI
37. Rimassa L, Personeni N, Czauderna C, Foerster F, Galle P. Systemic treatment of HCC in special populations. J Hepatol 2020;74:931-
43. DOI PubMed
38. Iavarone M, Invernizzi F, Czauderna C, et al. Preliminary experience on safety of regorafenib after sorafenib failure in recurrent
hepatocellular carcinoma after liver transplantation. Am J Transplant 2019;19:3176-84. DOI PubMed
39. Sposito C, Mariani L, Germini A, et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular
carcinoma after liver transplantation: a case-control study. J Hepatol 2013;59:59-66. DOI PubMed
40. Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.
Gut 2021;70:204-14. DOI PubMed PMC
